| Janice Jones-payne, | |
|
650 Murray Ln Unit 201, Des Plaines, IL 60016-5603 | |
| (847) 828-0073 | |
| Not Available |
| Full Name | Janice Jones-payne |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 650 Murray Ln Unit 201, Des Plaines, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144801275 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 043063182 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Janice Jones-payne, 650 Murray Ln Unit 201, Des Plaines, IL 60016-5603 Ph: (847) 828-0073 | Janice Jones-payne, 650 Murray Ln Unit 201, Des Plaines, IL 60016-5603 Ph: (847) 828-0073 |
News Archive
According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.
New information about how and where the innate immune system fights off viral infections that enter through the skin could lead to better treatments for viruses like Zika, dengue and measles, according to Penn State College of Medicine researchers.
Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology (IMO) at Moffitt Cancer Center, and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.
BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering. The investors are Great Point Partners, LLC and Deerfield Management Company. BioSante expects to receive net proceeds of approximately $17.5 million after deducting placement agent fees and other offering expenses.
Researchers from the Molecular Mechanisms and Experimental Therapy in Oncology program of the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology, together with the Biodonostia Health Research Institute, among others, have published in Nutrients the results of a multicenter study that unveils a correlation between inflammatory and antioxidant diets and the risk of developing colorectal and breast cancer.
› Verified 4 days ago